These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37479487)

  • 1. Severe cardiotoxicity induced by osimertinib in a patient with EGFR-mutated adenocarcinoma of the lung.
    Tanaka T; Nii S; Yamaoka H; Fujimoto N
    BMJ Case Rep; 2023 Jul; 16(7):. PubMed ID: 37479487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Osimertinib for an Elderly Patient with Adenocarcinoma of the Lung Harboring EGFR T790M Mutation Diagnosed Using a Pleural Fluid Cell Block].
    Nakao M; Suzuki Y; Arakawa S; Sakai Y; Fujita K; Ishikawa M; Sato H; Muramatsu H
    Gan To Kagaku Ryoho; 2018 Aug; 45(8):1177-1180. PubMed ID: 30158414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of 3rd generation TKI in patients with EGFR mutation lung adenocarcinoma with bone metastases: A review of 3 case reports and literature.
    Guo Q; Feng W; Hu S; Ye J; Wang S; Su L; Zhang Y; Zhang D; Zhang W; Xu J; Wei Y
    Medicine (Baltimore); 2023 Aug; 102(34):e34545. PubMed ID: 37653755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R.
    Makimoto G; Ninomiya K; Kubo T; Sunami R; Kato Y; Ichihara E; Ohashi K; Rai K; Hotta K; Tabata M; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2021 May; 51(6):956-965. PubMed ID: 33829270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential small cell transformation and T790M mutation in an epidermal growth factor-mutant lung adenocarcinoma: A rare occurrence with significant management implications.
    Shastri M; Gupta P; Gupta N; Singh N; Bal A; Srinivasan R; Khosla D
    Cytopathology; 2022 Nov; 33(6):732-737. PubMed ID: 35867808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma.
    Bardaro F; Stirpe E
    J Oncol Pharm Pract; 2022 Jun; 28(4):989-994. PubMed ID: 35037771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma: A case report.
    Inagaki Y; Tamiya A; Matsuda Y; Azuma K; Adachi Y; Enomoto T; Kouno S; Taniguchi Y; Saijo N; Okishio K; Atagi S
    Medicine (Baltimore); 2020 Oct; 99(42):e22628. PubMed ID: 33080698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological transformation of lung adenocarcinoma to small cell lung cancer with mutant C797S conferring acquired resistance to osimertinib.
    Ren X; Cai X; Li J; Zhang X; Yu J; Song X; Zhang H; Song X
    J Int Med Res; 2020 Jun; 48(6):300060520927918. PubMed ID: 32600081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation.
    Kawamura T; Kenmotsu H; Kobayashi H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Endo M; Takahashi T
    Invest New Drugs; 2020 Feb; 38(1):194-201. PubMed ID: 31183631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
    Akamatsu H; Toi Y; Hayashi H; Fujimoto D; Tachihara M; Furuya N; Otani S; Shimizu J; Katakami N; Azuma K; Miura N; Nishino K; Hara S; Teraoka S; Morita S; Nakagawa K; Yamamoto N
    JAMA Oncol; 2021 Mar; 7(3):386-394. PubMed ID: 33410885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports.
    Li G; Fang M; Zhou Y; Liu X; Tian P; Mei F
    Heliyon; 2023 Oct; 9(10):e20690. PubMed ID: 37860534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumatosis intestinalis induced by osimertinib in a patient with lung adenocarcinoma harbouring epidermal growth factor receptor gene mutation with simultaneously detected exon 19 deletion and T790 M point mutation: a case report.
    Nukii Y; Miyamoto A; Mochizuki S; Moriguchi S; Takahashi Y; Ogawa K; Murase K; Hanada S; Uruga H; Takaya H; Morokawa N; Kishi K
    BMC Cancer; 2019 Feb; 19(1):186. PubMed ID: 30819142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-generation sequencing clarified why first-line treatment with osimertinib was ineffective in an autopsied case of EGFR-mutated lung squamous cell carcinoma.
    Nishimura T; Fujiwara T; Fujimoto H; Tarumi H; Tsuji C; Iwanaka S; Sakakura Y; Naito M; Okugawa Y; Yasuma T; Gabazza EC; Oomoto Y; Kobayashi T; Ibata H
    Thorac Cancer; 2023 Mar; 14(7):709-713. PubMed ID: 36710365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation.
    Niwa H; Nakahara Y; Sasaki J; Masuda N
    BMJ Case Rep; 2018 Jun; 2018():. PubMed ID: 29866661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Pleural Effusion on Outcomes of Patients Receiving Osimertinib for NSCLC Harboring
    Masuhiro K; Shiroyama T; Suzuki H; Takata SO; Nasu S; Takada H; Morita S; Tanaka A; Morishita N; Okamoto N; Hirashima T
    Anticancer Res; 2018 Jun; 38(6):3567-3571. PubMed ID: 29848711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion.
    Nokihara H; Ogino H; Mitsuhashi A; Kondo K; Ogawa E; Ozaki R; Yabuki Y; Yoneda H; Otsuka K; Nishioka Y
    BMC Cancer; 2022 Jun; 22(1):597. PubMed ID: 35650550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study).
    Hiranuma O; Uchino J; Yamada T; Chihara Y; Tamiya N; Kaneko Y; Yoshimura K; Takayama K
    Clin Lung Cancer; 2019 May; 20(3):e402-e406. PubMed ID: 30905617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report.
    Taniguchi Y; Horiuchi H; Morikawa T; Usui K
    Case Rep Oncol; 2018; 11(2):323-329. PubMed ID: 29928211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful neoadjuvant treatment of EGFR exon 19 deletion combined with TP53 mutation in non-small cell lung cancer using aumolertinib after osimertinib-induced myocardial damage: a case report and literature review.
    Zhang G; Tang X; Zhang X; Qiu X; Lai Q; Li J
    Anticancer Drugs; 2023 Sep; 34(8):954-961. PubMed ID: 36800249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
    Herbst RS; Wu YL; John T; Grohe C; Majem M; Wang J; Kato T; Goldman JW; Laktionov K; Kim SW; Yu CJ; Vu HV; Lu S; Lee KY; Mukhametshina G; Akewanlop C; de Marinis F; Bonanno L; Domine M; Shepherd FA; Urban D; Huang X; Bolanos A; Stachowiak M; Tsuboi M
    J Clin Oncol; 2023 Apr; 41(10):1830-1840. PubMed ID: 36720083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.